Current Report Filing (8-k)
25 April 2022 - 10:01PM
Edgar (US Regulatory)
0001385818
false
0001385818
2022-04-25
2022-04-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 25, 2022
AYTU
BIOPHARMA, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-38247 |
|
47-0883144 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
373 Inverness Parkway, Suite
206
Englewood, CO 80112
(Address of principal executive offices, including
Zip Code)
Registrant’s telephone number, including
area code: (720) 437-6580
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
AYTU |
|
The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
On April 25, 2022, the Company issued a press
release announcing the positive results from a pre-clinical pilot study whereby administration of the Healight ultraviolet light A
(UVA) endotracheal catheter delayed time to development of ventilator-associated pneumonia (VAP) in a novel porcine model. A copy of
the press release is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
* In accordance with General Instruction B.2 of Form 8-K,
the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall
be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AYTU BIOPHARMA, INC. |
|
|
Date: April 25, 2022 |
By: |
/s/
Mark Oki |
|
|
Mark Oki |
|
|
Chief Financial Officer |
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Mar 2024 to Apr 2024
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Apr 2023 to Apr 2024